Liquidia Corporation (LQDA) News
Follow Liquidia Corporation (LQDA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 32 public stories across 18 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Atrium Therapeutics Q3 Collaboration Revenue Rises on BMS Milestone
EQUITY | Nov 12, 2026, 09:18 PM UTC
M
Liquidia Sets Nov. 10 Date to Report Third-Quarter 2026 Results
Liquidia Corporation said it will report its third-quarter 2026 financial results on Nov. 10, 2026.
EQUITY | Nov 03, 2026, 01:32 PM UTC
M
LQDA Q3'26 Earnings Preview
Liquidia Corporation is scheduled to report Q3'26 results on November 10; the time is unspecified.
EQUITY | Nov 03, 2026, 12:00 PM UTC
M
Liquidia Settles Six Patent Lawsuits With United Therapeutics
Liquidia settled six lawsuits with United Therapeutics, ending multiyear litigation over sales of its Yutrepia drug. Liquidia shares surged nearly 30% this morning.
EQUITY | Oct 14, 2026, 02:24 PM UTC
M
Liquidia Surges Nearly 37% After Settling United Therapeutics Litigation
Liquidia shares jumped nearly 37% in premarket trading after the drugmaker settled a years-long legal dispute with United Therapeutics over its lung disease drug. The settlement ends six lawsuits over patents, trade secr
EQUITY | Oct 14, 2026, 12:57 PM UTC
M
Liquidia Settles Lung Drug Dispute With United Therapeutics for $381 Million
The settlement ends six lawsuits over patents, trade secrets and contracts. Liquidia shares jumped nearly 40% in premarket trading Wednesday.
EQUITY | Oct 14, 2026, 11:50 AM UTC
M
U.S. Stock Futures Rise as Investors Await September CPI Report
U.S. stock futures rose Wednesday ahead of the September CPI release. The Dow Jones, S&P 500 and Nasdaq 100 were higher after Tuesday’s lower close.
EQUITY | Oct 14, 2026, 09:56 AM UTC
M
Liquidia, United Therapeutics Settle Patent Dispute, Keeping Yutrepia on Market
Liquidia announced a global settlement with United Therapeutics, ending years of litigation and securing continued sales of its Yutrepia inhalation powder for pulmonary arterial hypertension.
EQUITY | Oct 13, 2026, 11:40 PM UTC
M
Liquidia to Pay $380.7 Million to Settle United Therapeutics Lawsuits
Liquidia said it reached an agreement with United Therapeutics that resolves all pending litigation between the companies. The $380.7 million will be paid in multiple installments this year and next.
EQUITY | Oct 13, 2026, 10:54 PM UTC
M
Liquidia, United Therapeutics Settle All Pending Litigation
Liquidia says the global settlement ensures continued commercialization of YUTREPIA in PAH.
EQUITY | Oct 13, 2026, 09:50 PM UTC
H
Liquidia Shares Plunge After Court Ruling Invalidates Yutrepia Patent
Liquidia (LQDA) shares fell sharply after a Delaware court ruled that its inhaled drug Yutrepia infringes on two claims of a United Therapeutics (UTHR) patent. The ruling follows a 57% drop in LQDA shares on Wednesday.
REGULATION | Oct 01, 2026, 06:08 PM UTC
H
Progress Software, Nft And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 200 points on Thursday. Shares of Progress Software Corp (NASDAQ: PRGS ) fell sharply in pre-market trading after the company reported third
LIVE | Oct 01, 2026, 12:01 PM UTC
M
United Therapeutics seeks FDA withdraw of Yutrepia approval
United Therapeutics believes it is entitled to an order instructing the FDA to withdraw the approval of Liquidia's new drug application for Yutrepia.
REGULATION | Sep 30, 2026, 11:23 PM UTC
M
United Therapeutics wins patent infringement ruling against Liquidia Technologies
The District Court for the District of Delaware ruled that Liquidia Technologies, Inc. infringes two claims of a patent held by United Therapeutics.
REGULATION | Sep 30, 2026, 11:23 PM UTC
M
Liquidia: Court finds patent claims valid and infringed on YUTREPIA
Liquidia Corp said a Delaware court ruled that two claims of U.S. Patent No. 11,826,327 are valid and infringed as to YUTREPIA. The parties are expected to propose remedies.
EQUITY | Sep 30, 2026, 09:33 PM UTC
H
Liquidia Shares Plunge After Court Rules Against Lung Drug Patent
Liquidia's shares dropped nearly 50% after a federal judge ruled that its lung drug infringes a key patent held by United Therapeutics, significantly impacting the drug's commercial prospects.
REGULATION | Sep 30, 2026, 07:46 PM UTC
M
LQDA cites YUTREPIA growth and pipeline expansion powering profitability
LQDA says YUTREPIA’s launch has driven rapid revenue and patient growth, with strong adoption among naive patients and switches. It points to multiple late-stage trials, including L606, and expansion into PH-COPD and Ray
EQUITY | Sep 08, 2026, 02:20 PM UTC
M
LQDA touts commercial growth and expanding clinical pipeline
YUTREPIA launch drove rapid revenue and patient growth, with adoption in PAH and PH-ILD. The company says its pipeline is expanding, including L606 for broader indications and improved tolerability, supporting sustained
EQUITY | Sep 08, 2026, 01:43 PM UTC
M
Liquidia wins FDA Fast Track for YUTREPIA in SSc—RP
Liquidia (LQDA) received FDA Fast Track for YUTREPIA inhalation powder in SSc—RP. The company is preparing a ~75-patient Phase 2a RE—WARM trial, enrolling Oct 2026 and targeting primary completion Feb 2027.
REGULATION | Sep 07, 2026, 11:22 AM UTC
L
Liquidia gets FDA Fast Track for YUTREPIA in Raynaud's
Liquidia said the FDA granted Fast Track designation to YUTREPIA (treprostinil) inhalation powder for Raynaud’s phenomenon associated with systemic sclerosis.
REGULATION | Sep 03, 2026, 12:03 PM UTC
L
LQDA gets FDA Fast Track for YUTREPIA® in Raynaud’s
FDA granted Fast Track designation to YUTREPIA® for treating Raynaud’s phenomenon associated with systemic sclerosis.
REGULATION | Sep 03, 2026, 11:30 AM UTC
L
Liquidia to present two posters at ERS 2026 Congress
Liquidia Corporation said it will present two posters at the European Respiratory Society (ERS) 2026 Congress.
GEOPOLITICS | Sep 02, 2026, 12:37 PM UTC
H
LQDA - Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress
LQDA - Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress
GEOPOLITICS | Sep 02, 2026, 12:31 PM UTC
L
Liquidia management to speak at Wells Fargo healthcare conference
Liquidia Corporation says Michael Kaseta (COO and CFO) and Jason Adair (Chief Business Officer) will join a fireside chat at the Wells Fargo Annual Healthcare Conference.
EQUITY | Sep 01, 2026, 12:37 PM UTC
L
Liquidia to participate in Wells Fargo Annual Healthcare Conference
Liquidia Corporation said it will participate in the Wells Fargo Annual Healthcare Conference.
EQUITY | Sep 01, 2026, 12:30 PM UTC
L
LQDA Reports Second Quarter 2026 Financial Results
LQDA reports second quarter 2026 financial results
EARNINGS | Aug 12, 2026, 10:30 AM UTC
L
LQDA - Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026
LQDA - Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026
EARNINGS | Jul 29, 2026, 12:31 PM UTC
L
LQDA highs +7%
LQDA highs +7%
EQUITY | Jul 22, 2026, 03:38 PM UTC
L
Liquidia Insider Sold Shares Worth $1,053,926, According to a Recent SEC Filing
() -- Russell Schundler, General Counsel, on July 10, 2026, sold 14,738 shares in Liquidia (LQDA) for $1,053,926. Following the Form 4 filing with the SEC, Schundler has control over a total of 620,462 common shares of t
REGULATION | Jul 15, 2026, 08:07 AM UTC
L
Liquidia Insider Sold Shares Worth $1,986,695, According to a Recent SEC Filing
() -- Stephen M Bloch, Director, on July 01, 2026, sold 25,000 shares in Liquidia (LQDA) for $1,986,695. Following the Form 4 filing with the SEC, Bloch has control over a total of 926,667 common shares of the company, w
REGULATION | Jul 06, 2026, 09:48 PM UTC
M
LQDA Reports Q1
Liquidia reports first-quarter financial results with 44% sequential growth in net product sales and achieves a half-billion-dollar annualized revenue run rate for Eutrepia
EARNINGS | Jun 26, 2026, 08:35 AM UTC
M
LQDA: BTIG Raises Target
BTIG maintains buy rating on Liquidia and raises price target to $109
EQUITY | Jun 22, 2026, 10:45 AM UTC